GRCE
NASDAQ · Pharmaceuticals
Grace Therapeutics Inc
$4.42
+0.04 (+0.91%)
Financial Highlights (FY 2025)
Revenue
19.56M
Net Income
2.85M
Gross Margin
63.0%
Profit Margin
14.6%
Rev Growth
+16.3%
D/E Ratio
0.50
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 63.0% | 63.0% | 63.0% |
| Operating Margin | 18.6% | 20.1% | 18.6% |
| Profit Margin | 14.6% | 11.7% | 14.2% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 19.56M | 18.44M | 15.17M |
| Gross Profit | 12.32M | 11.62M | 9.56M |
| Operating Income | 3.63M | 3.71M | 2.83M |
| Net Income | 2.85M | 2.16M | 2.15M |
| Gross Margin | 63.0% | 63.0% | 63.0% |
| Operating Margin | 18.6% | 20.1% | 18.6% |
| Profit Margin | 14.6% | 11.7% | 14.2% |
| Rev Growth | +16.3% | +19.0% | +18.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 10.36M | 10.33M | 10.78M |
| Total Equity | 20.75M | 18.28M | 18.26M |
| D/E Ratio | 0.50 | 0.57 | 0.59 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 5.50M | 5.11M | 4.77M |
| Free Cash Flow | 2.45M | 3.17M | 1.86M |